Cargando…

The COVID-19 pandemic and heart failure: lessons from GUIDE-HF( )

Detalles Bibliográficos
Autores principales:	Cowie, Martin R, Cleland, John G F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279113/ https://www.ncbi.nlm.nih.gov/pubmed/35511076 http://dx.doi.org/10.1093/eurheartj/ehac226

Ejemplares similares

Geographic variations in the PARADIGM-HF heart failure trial
por: Kristensen, Søren Lund, et al.
Publicado: (2016)

Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE‐HF extended trial
por: Kleiner Shochat, Michael, et al.
Publicado: (2018)

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
por: Docherty, Kieran F, et al.
Publicado: (2020)

Protocol for an implementation study of an evidence-based home cardiac rehabilitation programme for people with heart failure and their caregivers in Scotland (SCOT:REACH-HF)
por: Purcell, Carrie, et al.
Publicado: (2020)

STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
por: Cannone, Valentina, et al.
Publicado: (2021)

Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)
por: McMurray, John J.V., et al.
Publicado: (2013)

Effects of person-centred care in patients with chronic heart failure: the PCC-HF study
por: Ekman, Inger, et al.
Publicado: (2012)

Remote Management of Heart Failure: An Overview of Telemonitoring Technologies
por: Brahmbhatt, Darshan H, et al.
Publicado: (2019)

Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE‐HF trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Association of time‐to‐intravenous furosemide with mortality in acute heart failure: data from REPORT‐HF
por: Ouwerkerk, Wouter, et al.
Publicado: (2022)

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA‐HF
por: Adamson, Carly, et al.
Publicado: (2022)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population
por: Straburzyńska-Migaj, Ewa, et al.
Publicado: (2015)

Health Care Delivery for Heart Failure Patients During The COVID-19 Pandemic; A Consensus of The Saudi Heart Failure Working Group (SAUDI-HF)
por: Bakhsh, Abeer, et al.
Publicado: (2020)

Adaptive servo ventilation for central sleep apnoea in heart failure: SERVE-HF on-treatment analysis
por: Woehrle, Holger, et al.
Publicado: (2017)

A comparison of non‐invasive methods of measuring body composition in patients with heart failure: a report from SICA‐HF
por: Shah, Parin, et al.
Publicado: (2021)

Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial
por: Halliday, Brian P, et al.
Publicado: (2019)

Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials
por: Wijkman, Magnus O., et al.
Publicado: (2022)

Effects of Omecamtiv Mecarbil on Symptoms and Health-Related Quality of Life in Patients With Chronic Heart Failure: Results From the COSMIC-HF Study
por: Felker, G. Michael, et al.
Publicado: (2020)

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)
por: von Haehling, Stephan, et al.
Publicado: (2010)

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
por: Mehra, Mandeep R, et al.
Publicado: (2019)

The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial
por: Wikstrom, Gerhard, et al.
Publicado: (2009)

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)
por: Serenelli, Matteo, et al.
Publicado: (2020)

Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial
por: Metra, Marco, et al.
Publicado: (2022)

Impact of COVID-19 on heart failure hospitalization and outcome in India – A cardiological society of India study (CSI–HF in COVID 19 times study – “The COVID C–HF study”)
por: B, Jayagopal P., et al.
Publicado: (2023)

Cardiac inflammation in COVID-19: Lessons from heart failure
por: Unudurthi, Sathya D., et al.
Publicado: (2020)

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
por: Butt, Jawad H, et al.
Publicado: (2023)

The Heart Failure Optimization Study (HF-OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

Quality of life in heart failure patients undergoing hybrid comprehensive telerehabilitation versus usual care – results of the Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial
por: Piotrowicz, Ewa, et al.
Publicado: (2020)

Decrease in the 30-day heart failure (HF) Rehospitalization Rate after the implementation of a HF managed protocol
por: Correa, AG, et al.
Publicado: (2009)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial
por: Keene, Daniel, et al.
Publicado: (2018)

Impact of COVID‐19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV‐HF‐SIRIO 6 study)
por: Kubica, Jacek, et al.
Publicado: (2021)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Telemedicine: an Effective and Low-Cost Lesson From the COVID-19 Pandemic for the Management of Heart Failure Patients
por: Severino, Paolo, et al.
Publicado: (2023)

Prevalence and inter-relationship of different Doppler measures of dyssynchrony in patients with heart failure and prolonged QRS: a report from CARE-HF
por: Edner, Magnus, et al.
Publicado: (2009)

Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial
por: Morrow, David A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t3307brqmecmgik2a61t3plct0